Endocrine Abstracts

March 2011. Patient P. Caucasian female, 53 years. Diagnosis: severe Grave’s disease (GD), recurrent course. Endocrine ophthalmopathy (EO) NOSPECS – 4, CAS – 7. Thyrotoxic cardiomyopathy. Paroxysmal atrial fibrillation. Thyrotoxic proximal myopathy of the lower limbs. Thyrotoxic hepatitis. Type 2 diabetes mellitus. Chronic obstructive pulmonary disease.Anamnesis: GD was first diagnosed in 2001, when she started to complain of weight lost (...

Patients with diabetes mellitus (DM) are more likely to suffer from purulent infection, probably due to compromised immune response. Achieving target levels of glycemia is a prerequisite for the perioperative management of patients with DM. However, the specific parameters of glycemic variability, optimal glucose range for the effective treatment of purulent infection of the maxillofacial region have not been established yet.Purpose: to assess the impact...

Purpose : To determine the effective and safe regimen of glucocorticoids administration in patients with COVID-19 and with or without DM.Materials and methods: We examined 276 patients with covid-19 and polysegmental pneumonia with CT (1-4) in inpatient treatment with an oxygen support level of up to 15 liters per minute, all patients were discharged from the hospital. Patients were divided into 2 groups according to the therapy they received. The first ...

Patient C Caucasian male, 41 years old was admitted to the inpatient department of endocrinology with newly diagnosed T2 DM, morbid obesity on the 03.03.2011.Anamnesis: Overweight since childhood, but in the past few years he started to gain weight rapidly (because of smoking cessation). Arterial hypertension since 2003, with maximum increase up to 210/125 and he took antihypertensive drugs regularly. In 2006 painless myocardial ischemia was f...

Introduction: DDP4i improves the function of β-cells and α-cells. However, there have been short-term follow-up and young subjects in many experimental and clinical studies. The imbalance of pancreatic endocrinocytes increases in adulthood and changes become less reversible. We decided that it would be useful to study the morphofunctional features of pancreatic endocrinocytes while taking iDPP4 in the older age group in the clinic and experimentally.<p class="abs...

Introduction: New medicinal products that have been introduced into first-line therapy for type 2 diabetes mellitus (T2DM) include glucagon-like peptide-1 receptor agonists (GLP-1ra) and dipeptidyl peptidase-4 inhibitors (DPP-4i). These products have been shown to increase beta-cell proliferation. Some studies also demonstrated an increase in pancreatic alpha-cell proliferation. Various sulfonylureas drugs (SU) have been shown to produce different effects on apoptosis pancreat...

Bronchopulmonary endocrine tumors represent 25–30% of lung neoplasms. Surgery provides good survival for differentiated tumors (typical and atypical carcinoids), but is not useful for aggressive poorly differentiated forms. Somatostatin (SRIF) analogs can be used as medical therapy, prolonging patient survival. However, the compounds employed so far did not display antiproliferative effects. Recently, a new stable SRIF analog, pasireotide (SOM230), which activates SSTR1, ...

Somatostatin (SRIH) inhibits cell proliferation by interacting with five distinct SRIH receptor subtypes (SSTR) by several pathways in many tissues. We previously demonstrated that SRIH, by activating SHP-1, inhibits cell proliferation of the human Medullary Thyroid Carcinoma (MTC) cell line, TT, which expresses all SSTR. However, the effects of SRIH on cell cycle proteins have not been investigated, so far. We therefore investigated the effects of SRIH and of a selective SSTR...

Medullary thyroid carcinoma (MTC) is a malignant tumour deriving from parafollicular C cells, with a highly chemoresistant phenotype. Failure of medical therapy has been ascribed, at least in part, to multi drug resistance (MDR1) gene over-expression. MDR1 encodes for a transmembrane glycoprotein, P-gp, which hampers intracellular accumulation of cytotoxic drugs. It has been demonstrated that P-gp expression and function depend on cyclo-oxygenase 2 (COX-2) expression, which is...

Dopamine (DA) therapy of non-functioning pituitary adenomas (NFA) can result in tumor stabilization and shrinkage. However, this effect is not always apparent and the mechanism of action is still unknown. Previous evidence showed that DA inhibits pituitary Vascular Endothelial Growth Factor expression (VEGF), that, in turn, is related to pituitary tumor growth. Our study aimed at clarifying whether VEGF secretion modulation might mediate the effects of DA agonists and chimeric...